| abstract |
The medicinal product comprises as active prin-ciple a melarsomine hydrochloride preparation having a purity of between 98.5 and 100 %. The process for obtaining this preparation is stated essentially as follows: - step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium; - step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid; - step 3, the MAH is reduced to melarsen oxide dehydrate; and - step 4, the melarsen oxide dehydrate is converted to melarsomine dihydrochloride in the presence of cystea-mine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained. |